| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
Acetrizoate sodium functions as a radiographic contrast agent rather than targeting a specific biological receptor or enzyme. Its mechanism of action is physical rather than pharmacological: the high iodine content of the molecule absorbs X-rays, providing contrast between different tissues and allowing visualization of anatomical structures during X-ray imaging. The compound is administered intravenously or via other routes to opacify blood vessels, organs, or body cavities during diagnostic procedures.
|
|---|---|
| ln Vitro |
Acetrizoate sodium is not typically evaluated for in vitro biological activity in the same way as therapeutic compounds. Its activity is measured by its ability to provide radiographic contrast in imaging studies. The compound's high iodine content (three iodine atoms per molecule) provides excellent X-ray absorption properties. In vitro studies may focus on its physicochemical properties, stability, and compatibility with biological fluids rather than on receptor binding or enzyme inhibition.
|
| ln Vivo |
Acetrizoate sodium is used as a radiographic contrast agent in diagnostic imaging procedures. It is administered intravenously or via other routes to provide contrast in X-ray imaging of blood vessels, organs, and body cavities. The compound's efficacy is measured by its ability to enhance image quality and provide diagnostic information. Its safety profile has been evaluated in clinical studies, with known risks including allergic reactions and nephrotoxicity.
|
| Enzyme Assay |
Physicochemical characterization of Acetrizoate sodium including solubility, stability, and iodine content. Radiographic contrast properties are evaluated by measuring X-ray attenuation using phantoms or in vitro imaging systems. The compound's compatibility with biological fluids is assessed by measuring osmolality, viscosity, and pH. Protein binding studies may be performed using dialysis or ultrafiltration methods to determine the fraction of compound bound to plasma proteins.
|
| Cell Assay |
In vitro cell-based assays using renal cell lines or other relevant cell types to evaluate the cytotoxicity and potential nephrotoxicity of Acetrizoate sodium. Cells are treated with Acetrizoate sodium at various concentrations (typically 1-100 mM) for specified durations. Cell viability is assessed using MTT or LDH release assays. Cellular uptake and accumulation of the compound may be measured using iodine-specific detection methods. The compound's effects on renal cell function, including markers of tubular injury, may be evaluated.
|
| Animal Protocol |
In vivo studies in animal models to evaluate the pharmacokinetics, biodistribution, and toxicity of Acetrizoate sodium. The compound is administered via intravenous injection at doses relevant to clinical use. Blood and urine samples are collected at various time points to measure drug concentrations and renal clearance. Imaging studies are performed to evaluate contrast enhancement in various tissues. Histopathological analysis of organs, particularly the kidneys, is performed to assess toxicity. Pharmacokinetic parameters including half-life, volume of distribution, and clearance are determined.
|
| References |
|
| Additional Infomation |
Iodinated radioactive contrast agents, such as sodium ethidium iodide used in hysterosalpingography.
|
| Molecular Formula |
C9H5I3NNAO3
|
|---|---|
| Molecular Weight |
578.8427
|
| Exact Mass |
578.73
|
| CAS # |
129-63-5
|
| PubChem CID |
23665874
|
| Appearance |
Typically exists as solid at room temperature
|
| Boiling Point |
547.1ºC at 760 mmHg
|
| Flash Point |
284.7ºC
|
| Vapour Pressure |
8.39E-13mmHg at 25°C
|
| LogP |
1.895
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
17
|
| Complexity |
305
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[Na+].CC(NC1=C(I)C=C(I)C(C([O-])=O)=C1I)=O
|
| InChi Key |
UCPVOMHRDXMAIZ-UHFFFAOYSA-M
|
| InChi Code |
InChI=1S/C9H6I3NO3.Na/c1-3(14)13-8-5(11)2-4(10)6(7(8)12)9(15)16/h2H,1H3,(H,13,14)(H,15,16)/q+1/p-1
|
| Chemical Name |
sodium 3-acetamido-2,4,6-triiodobenzoate
|
| Synonyms |
Acetrizoate sodium Sodium acetrizoateReopak DiaginolMP 1023 MP1023MP-1023
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7276 mL | 8.6380 mL | 17.2759 mL | |
| 5 mM | 0.3455 mL | 1.7276 mL | 3.4552 mL | |
| 10 mM | 0.1728 mL | 0.8638 mL | 1.7276 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
